LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Baxter International Inc

Closed

SectorHealthcare

19.17 0.58

Overview

Share price change

24h

Current

Min

19.02

Max

19.65

Key metrics

By Trading Economics

Income

1B

-15M

Sales

-273M

2.7B

P/E

Sector Avg

86.308

49.701

EPS

0.36

Dividend yield

2.08

Profit margin

-0.555

Employees

37,500

EBITDA

750M

303M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+11.09% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.08%

2.39%

Next Earnings

30 Jul 2026

Next Dividend date

1 Jul 2026

Next Ex Dividend date

29 May 2026

Market Stats

By TradingEconomics

Market Cap

-358M

9.2B

Previous open

18.59

Previous close

19.17

News Sentiment

By Acuity

27%

73%

148 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Baxter International Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Feb 2026, 20:10 UTC

Earnings

Baxter Is One of the S&P 500's Worst Performers Today. Earnings Were Brutal. -- Barrons.com

12 Feb 2026, 14:43 UTC

Earnings

Baxter Is One of the S&P 500's Worst Performers Today. Earnings Were Brutal. -- Barrons.com

Peer Comparison

Price change

Baxter International Inc Forecast

Price Target

By TipRanks

11.09% upside

12 Months Forecast

Average 21.14 USD  11.09%

High 27 USD

Low 17 USD

Based on 8 Wall Street analysts offering 12 month price targets forBaxter International Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

8 ratings

2

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

30.475 / 31.345Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

148 / 345 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
help-icon Live chat